Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Fatty Liver
Adam's Take

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

By Adam Feuerstein

Hepatitis Drugs
Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

By Adam Feuerstein

Close-up eye
Biotech

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

By Adam Feuerstein

Adam's Take

Lipocine fatty liver drug study results don’t hold up to scrutiny

By Adam Feuerstein

JPM 2019 - Painted Ladies
Adam's Take

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

By Adam Feuerstein

JPM 2019 - Painted Ladies
Adam's Take

It’s day one at JPM19. Here’s what we heard and learned

By Adam Feuerstein

Westin St. Francis hotel
Adam's Take

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

By Adam Feuerstein

Good/Bad CEO 2017
Adam's Take

Leiden victorious in best biopharma CEO tally; Alles tops worst list

By Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Adam's Take

If biotech stock values are down, why isn’t M&A picking up?

By Adam Feuerstein

Stock market dystopia
Adam's Take

Biotech is looking woozy: ferocious selling and a sense of foreboding

By Adam Feuerstein

Adam's Take

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

By Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

By Adam Feuerstein

Pick A Card
Adam's Take

Acadia Pharma conjures black magic to spin a failed depression drug trial

By Adam Feuerstein

Squamous_carcinoma_lung_cytology
Adam's Take

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

By Adam Feuerstein

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Fish oil pills on pink
Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Fish oil capsules
Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy